News | October 06, 2025
Lilly to invest $1 billion+ in new contract manufacturing in India
Investment to expand manufacturing and global medicine supply capacity
Investment to expand manufacturing and global medicine supply capacity
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
India currently hosts more than 10,075 biotech startups
Miels will formally assume the role on January 1, 2026
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
